CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL
Open Access
- 1 January 2026
- journal article
- Published by AME Publishing Company in Translational Breast Cancer Research
- Vol. 7, 10
Abstract
Editorial Commentary CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL Eriko TokunagaKeywords
This publication has 25 references indexed in Scilit:
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical TrialClinical Cancer Research, 2021
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialBreast Cancer Research, 2021
- Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalAnnals of Oncology, 2021
- Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARLAnnals of Oncology, 2021
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2JAMA Oncology, 2020
- Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trialThe Lancet Oncology, 2019
- Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trialsBreast Cancer Research and Treatment, 2015
- Biology of breast cancer in young womenBreast Cancer Research, 2014
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression ProfilingClinical Cancer Research, 2012